Oral paricalcitol for the treatment of secondary hyperparathyroidism in chronic kidney disease
نویسندگان
چکیده
منابع مشابه
Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
Secondary hyperparathyroidism (SHPT) is commonly seen in patients with chronic kidney disease (CKD). Even in early CKD, parathyroid hormone (PTH) levels are elevated, maintaining mineral homeostasis at the cost of long-term bone health. One potent stimulus for PTH secretion is a deficiency of active vitamin D. Replacement with calcitriol, the active form of vitamin D, lowers PTH but often raise...
متن کاملMeta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease
INTRODUCTION Previous studies have demonstrated the safety and efficacy of using Paricalcitol for the treatment of secondary hyperparathyroidism (SHPT) in patients on dialysis. The aim of the current meta-analysis was to assess the safety and efficacy of Paricalcitol for the management of SHPT in patients with chronic kidney disease (CKD) not yet on dialysis. A secondary aim was to determine if...
متن کاملSecondary hyperparathyroidism in chronic kidney disease
Chronic kidney failure is much more common than people realize, and often goes undetected and undiagnosed until the disease is well advanced and k function decreases it affects many other systems of the body mainly the calcium phosphorous metabolism as the metabolism is mainly controlled by kidney in terms of absor of calcium phosphorus. Secondary hyperparathyroidism is usually found in patient...
متن کاملParicalcitol for secondary hyperparathyroidism in renal transplantation.
Secondary hyperparathyroidism contributes to post-transplant CKD mineral and bone disorder. Paricalcitol, a selective vitamin D receptor activator, decreased serum parathyroid hormone levels and proteinuria in patients with secondary hyperparathyroidism. This single-center, prospective, randomized, crossover, open-label study compared the effect of 6-month treatment with paricalcitol (1 μg/d fo...
متن کاملSecondary Hyperparathyroidism and Chronic Kidney Disease
19 ro m R esarch to P ratice / D ab tic K id ey D isase Secondary hyperparathyroidism (SHPT) describes a complex alteration in bone and mineral metabolism that occurs as a direct result of chronic kidney disease (CKD). Bone disease, a well-recognized complication of SHPT, represents only a small concern in light of the evidence that correlates SHPT with cardiovascular disease and an increased r...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Therapeutics and Clinical Risk Management
سال: 2006
ISSN: 1176-6336
DOI: 10.2147/tcrm.2006.2.3.297